Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière’s Disease

Back to Jobs

SAN DIEGO , Feb. 22, 2021 (GLOBE NEWSWIRE) — Otonomy , Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the Phase 3 clinical trial of OTIVIDEX in patients with Ménière’s disease did not achieve the

Apply Now